You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
26 October 2026 - Danish biotechnology company Genmab A/S (CPH:GMAB) on Monday reported updated Phase 2 results showing median overall survival of 28.2 months with investigational petosemtamab plus pembrolizumab in first-line treatment of recurrent o...
26 October 2026 - Chinese biopharmaceutical company Akeso Inc (HKEX:9926) announced on Sunday the presentation of results from the randomised, controlled, double-blind, multicentre, registrational Phase III HARMONi-GI1 trial (AK112-309).The study eva...
26 October 2026 - Chinese biopharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (Kelun-Biotech) (HKG:6990) announced on Sunday the presentation at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, of ...
26 October 2026 - China-based Zhejiang Wenda Pharmaceutical Technology Co Ltd announced on Sunday the publication of its phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chinese patients with advanced NUT carcinoma (NC) at the...
26 October 2026 - Commercial-stage biopharmaceutical company Bio-Thera Solutions Ltd (SHA:688177) announced on Saturday the presentation of clinical data for BAT8008, a TROP2-targeted antibody-drug conjugate (ADC), in combination with BAT1308, an ant...
26 October 2026 - South Korea-based Lunit Inc (KRX:328130), a provider of AI solutions for cancer diagnostics and therapeutics, and US biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Friday a research agreement t...
23 October 2026 - RNAi (RNA interference) therapeutics company Alnylam Pharmaceuticals Inc (Nasdaq:ALNY) on Friday reported positive initial Phase 1b clinical trial results for brezosiran, an investigational RNAi therapy for Huntington's disease...